BACKGROUND: Making the distinction between primary mucinous and metastatic ovarian tumors is often difficult, especially in tumors with a primary source from the gastrointestinal tract, pancreas and biliary tree. The aim of the following paper is to provide an overview of the problematics, with a focus on the possibilities of the differential diagnosis at the macroscopic, microscopic and immunohistochemical level. MAIN BODY: The three main aspects of mucinous ovarian tumors are described in detail, including the comparison of the available diagnostic algorithms based on the evaluation of mostly macroscopic features, characterization of the spectrum of microscopic features, and a detailed analysis of the immunophenotype comparing 20 antibodies with the assessment of their statistical significance for differential diagnosis purposes. Specific features, including Krukenberg tumor and pseudomyxoma peritonei, are also discussed. CONCLUSION: Despite the growing knowledge of the macroscopic and microscopic features of ovarian mucinous tumors and the availability of a wide range of immunohistochemical antibodies useful in this setting, there still remains a group of tumors which cannot be precisely classified without close clinical-pathological cooperation.

Blizard Institute of Core Pathology Queen Mary University of London London UK

Department of Cellular Pathology Barts Health NHS Trust Queen Mary University of London London UK

Institute of Pathology 1st Faculty of Medicine Charles University and General University Hospital Prague Studničkova 2 128 00 Prague 2 Czech Republic

Zobrazit více v PubMed

Platz CE, Benda JA. Female genital tract cancer. Cancer. 1995;75(1 Suppl):270–294. doi: 10.1002/1097-0142(19950101)75:1+<270::AID-CNCR2820751312>3.0.CO;2-D. PubMed DOI

Mink PJ, Sherman ME, Devesa SS. Incidence patterns of invasive and borderline ovarian tumors among white women and black women in the United States. Results from the SEER program, 1978-1998. Cancer. 2002;95(11):2380–2389. doi: 10.1002/cncr.10935. PubMed DOI

Seidman JD, Kurman RJ, Ronnett BM. Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis. Am J Surg Pathol. 2003;27(7):985–993. doi: 10.1097/00000478-200307000-00014. PubMed DOI

Liu F, Gao Z, Shen D, Zhao H, Wang C, Ye Y, et al. Significance of SATB2 expression in colon cancer and its differential diagnosis in digestive tract adenocarcinoma and ovarian primary and metastatic carcinoma. Pathol Res Pract. 2019;215(7):152430. doi: 10.1016/j.prp.2019.04.022. PubMed DOI

Meagher NS, Wang L, Rambau PF, Intermaggio MP, Huntsman DG, Wilkens LR, et al. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Mod Pathol. 2019;32(12):1834–1846. doi: 10.1038/s41379-019-0302-0. PubMed DOI PMC

Aldaoud N, Erashdi M, AlKhatib S, Abdo N, Al-Mohtaseb A, Graboski-Bauer A. The utility of PAX8 and SATB2 immunohistochemical stains in distinguishing ovarian mucinous neoplasms from colonic and appendiceal mucinous neoplasm. BMC Res Notes. 2019;12(1):770. doi: 10.1186/s13104-019-4816-9. PubMed DOI PMC

Schmoeckel E, Kirchner T, Mayr D. SATB2 is a supportive marker for the differentiation of a primary mucinous tumor of the ovary and an ovarian metastasis of a low-grade appendiceal mucinous neoplasm (LAMN): a series of seven cases. Pathol Res Pract. 2018;214(3):426–430. doi: 10.1016/j.prp.2017.12.008. PubMed DOI

Park CK, Kim HS. Clinicopathological characteristics of ovarian metastasis from colorectal and Pancreatobiliary carcinomas mimicking primary ovarian mucinous tumor. Anticancer Res. 2018;38(9):5465–5473. doi: 10.21873/anticanres.12879. PubMed DOI

Li Z, Roth R, Rock JB, Lehman A, Marsh WL, Suarez A, et al. Dual immunostain with SATB2 and CK20 differentiates Appendiceal mucinous neoplasms from ovarian mucinous neoplasms. Am J Clin Pathol. 2017;147(5):484–491. doi: 10.1093/ajcp/aqx023. PubMed DOI PMC

Strickland S, Wasserman JK, Giassi A, Djordjevic B, Parra-Herran C. Immunohistochemistry in the diagnosis of mucinous neoplasms involving the ovary: the added value of SATB2 and biomarker discovery through protein expression database mining. Int J Gynecol Pathol. 2016;35(3):191–208. doi: 10.1097/PGP.0000000000000238. PubMed DOI

Moh M, Krings G, Ates D, Aysal A, Kim GE, Rabban JT. SATB2 expression distinguishes ovarian metastases of colorectal and Appendiceal origin from primary ovarian tumors of mucinous or Endometrioid type. Am J Surg Pathol. 2016;40(3):419–432. doi: 10.1097/PAS.0000000000000553. PubMed DOI

Perez Montiel D, Arispe Angulo K, Cantú-de León D, Bornstein Quevedo L, Chanona Vilchis J, Herrera ML. The value of SATB2 in the differential diagnosis of intestinal-type mucinous tumors of the ovary: primary vs metastatic. Ann Diagn Pathol. 2015;19(4):249–252. doi: 10.1016/j.anndiagpath.2015.05.004. PubMed DOI

Hu A, Li H, Zhang L, Ren C, Wang Y, Liu Y, et al. Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality. J Clin Pathol. 2015;68(7):522–528. doi: 10.1136/jclinpath-2015-202951. PubMed DOI PMC

Wang J, El-Bahrawy MA. Expression profile of mucins in ovarian mucinous tumors: distinguishing primary ovarian from metastatic tumors. Int J Gynecol Pathol. 2014;33(2):166–175. doi: 10.1097/PGP.0b013e318288b384. PubMed DOI

Almeida BG, Bacchi CE, Carvalho JP, Ferreira CR, Carvalho FM. The role of intratumoral lymphovascular density in distinguishing primary from secondary mucinous ovarian tumors. Clinics (Sao Paulo) 2014;69(10):660–665. doi: 10.6061/clinics/2014(10)02. PubMed DOI PMC

Pinto PB, Derchain SF, Andrade LA. Metastatic mucinous carcinomas in the ovary: a practical approach to diagnosis related to gross aspects and to immunohistochemical evaluation. Int J Gynecol Pathol. 2012;31(4):313–318. doi: 10.1097/PGP.0b013e31823f844d. PubMed DOI

Meriden Z, Yemelyanova AV, Vang R, Ronnett BM. Ovarian metastases of pancreaticobiliary tract adenocarcinomas: analysis of 35 cases, with emphasis on the ability of metastases to simulate primary ovarian mucinous tumors. Am J Surg Pathol. 2011;35(2):276–288. doi: 10.1097/PAS.0b013e31820508d0. PubMed DOI

Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, et al. CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol. 2010;40(3):208–213. doi: 10.1093/jjco/hyp150. PubMed DOI

Silverman JF, Zhu B, Liu Y, Lin X. Distinctive immunohistochemical profile of mucinous cystic neoplasms of pancreas, ovary and lung. Histol Histopathol. 2009;24(1):77–82. PubMed

Khunamornpong S, Lerwill MF, Siriaunkgul S, Suprasert P, Pojchamarnwiputh S, Chiangmai WN, et al. Carcinoma of extrahepatic bile ducts and gallbladder metastatic to the ovary: a report of 16 cases. Int J Gynecol Pathol. 2008;27(3):366–379. doi: 10.1097/PGP.0b013e31815d6903. PubMed DOI

Zapata M, Cohen C, Siddiqui MT. Immunohistochemical expression of SMAD4, CK19, and CA19-9 in fine needle aspiration samples of pancreatic adenocarcinoma: utility and potential role. Cytojournal. 2007;4:13. doi: 10.1186/1742-6413-4-13. PubMed DOI PMC

Vang R, Gown AM, Wu LS, Barry TS, Wheeler DT, Yemelyanova A, et al. Immunohistochemical expression of CDX2 in primary ovarian mucinous tumors and metastatic mucinous carcinomas involving the ovary: comparison with CK20 and correlation with coordinate expression of CK7. Mod Pathol. 2006;19(11):1421–1428. doi: 10.1038/modpathol.3800698. PubMed DOI

Lewis MR, Deavers MT, Silva EG, Malpica A. Ovarian involvement by metastatic colorectal adenocarcinoma: still a diagnostic challenge. Am J Surg Pathol. 2006;30(2):177–184. doi: 10.1097/01.pas.0000176436.26821.8a. PubMed DOI

Logani S, Oliva E, Arnell PM, Amin MB, Young RH. Use of novel immunohistochemical markers expressed in colonic adenocarcinoma to distinguish primary ovarian tumors from metastatic colorectal carcinoma. Mod Pathol. 2005;18(1):19–25. doi: 10.1038/modpathol.3800260. PubMed DOI

Kim MJ. The usefulness of CDX-2 for differentiating primary and metastatic ovarian carcinoma: an immunohistochemical study using a tissue microarray. J Korean Med Sci. 2005;20(4):643–648. doi: 10.3346/jkms.2005.20.4.643. PubMed DOI PMC

Chou YY, Jeng YM, Kao HL, Chen T, Mao TL, Lin MC. Differentiation of ovarian mucinous carcinoma and metastatic colorectal adenocarcinoma by immunostaining with beta-catenin. Histopathology. 2003;43(2):151–156. doi: 10.1046/j.1365-2559.2003.01687.x. PubMed DOI

Fraggetta F, Pelosi G, Cafici A, Scollo P, Nuciforo P, Viale G. CDX2 immunoreactivity in primary and metastatic ovarian mucinous tumours. Virchows Arch. 2003;443(6):782–786. doi: 10.1007/s00428-003-0910-3. PubMed DOI

Ji H, Isacson C, Seidman JD, Kurman RJ, Ronnett BM. Cytokeratins 7 and 20, Dpc4, and MUC5AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21(4):391–400. doi: 10.1097/00004347-200210000-00009. PubMed DOI

Dionigi A, Facco C, Tibiletti MG, Bernasconi B, Riva C, Capella C. Ovarian metastases from colorectal carcinoma. Clinicopathologic profile, immunophenotype, and karyotype analysis. Am J Clin Pathol. 2000;114(1):111–122. doi: 10.1309/G56H-97A2-JFMT-CD5N. PubMed DOI

Lagendijk JH, Mullink H, van Diest PJ, Meijer GA, Meijer CJ. Immunohistochemical differentiation between primary adenocarcinomas of the ovary and ovarian metastases of colonic and breast origin. Comparison between a statistical and an intuitive approach. J Clin Pathol. 1999;52(4):283–290. doi: 10.1136/jcp.52.4.283. PubMed DOI PMC

Wauters CC, Smedts F, Gerrits LG, Bosman FT, Ramaekers FC. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995;26(8):852–855. doi: 10.1016/0046-8177(95)90006-3. PubMed DOI

Ueda G, Sawada M, Ogawa H, Tanizawa O, Tsujimoto M. Immunohistochemical study of cytokeratin 7 for the differential diagnosis of adenocarcinomas in the ovary. Gynecol Oncol. 1993;51(2):219–223. doi: 10.1006/gyno.1993.1276. PubMed DOI

Moll R, Löwe A, Laufer J, Franke WW. Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 1992;140(2):427–447. PubMed PMC

Daya D, Nazerali L, Frank GL. Metastatic ovarian carcinoma of large intestinal origin simulating primary ovarian carcinoma. A clinicopathologic study of 25 cases. Am J Clin Pathol. 1992;97(6):751–758. doi: 10.1093/ajcp/97.6.751. PubMed DOI

Nonaka D, Chiriboga L, Soslow RA. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas. Am J Surg Pathol. 2008;32(10):1566–1571. doi: 10.1097/PAS.0b013e31816d71ad. PubMed DOI

Ritterhouse LL, Wu EY, Kim WG, Dillon DA, Hirsch MS, Sholl LM, et al. Loss of SMAD4 protein expression in gastrointestinal and extra-gastrointestinal carcinomas. Histopathology. 2019;75(4):546–551. doi: 10.1111/his.13894. PubMed DOI

Alghamdi S, Alghaashamy K, Pinto A. Expression of SMAD4 is retained in Most gynecologic tumors with mucinous differentiation. Int J Gynecol Pathol. 2019. PubMed

Bassiouny D, Ismiil N, Dubé V, Han G, Cesari M, Lu FI, et al. Comprehensive Clinicopathologic and updated Immunohistochemical characterization of primary ovarian mucinous carcinoma. Int J Surg Pathol. 2018;26(4):306–317. doi: 10.1177/1066896917752861. PubMed DOI

Zhu Q, Qu Y, Zhang Q, Lu L, Weng W, Zhang H, et al. IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression. Am J Transl Res. 2017;9(7):3387–3398. PubMed PMC

Wang J, El-Bahrawy M. Expression profile of mucins (MUC1, MUC2, MUC5AC, and MUC6) in ovarian mucinous tumours: changes in expression from benign to malignant tumours. Histopathology. 2015;66(4):529–535. doi: 10.1111/his.12578. PubMed DOI

Halimi SA, Maeda D, Shinozaki-Ushiku A, Koso T, Matsusaka K, Tanaka M, et al. Claudin-18 overexpression in intestinal-type mucinous borderline tumour of the ovary. Histopathology. 2013;63(4):534–544. PubMed

Tabrizi AD, Kalloger SE, Kobel M, Cipollone J, Roskelley CD, Mehl E, et al. Primary ovarian mucinous carcinoma of intestinal type: significance of pattern of invasion and immunohistochemical expression profile in a series of 31 cases. Int J Gynecol Pathol. 2010;29(2):99–107. doi: 10.1097/PGP.0b013e3181bbbcc1. PubMed DOI

McKenney JK, Soslow RA, Longacre TA. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei. Am J Surg Pathol. 2008;32(5):645–655. doi: 10.1097/PAS.0b013e31815b486d. PubMed DOI

Lin X, Lindner JL, Silverman JF, Liu Y. Intestinal type and endocervical-like ovarian mucinous neoplasms are immunophenotypically distinct entities. Appl Immunohistochem Mol Morphol. 2008;16(5):453–458. doi: 10.1097/PAI.0b013e3181672574. PubMed DOI

Vang R, Gown AM, Zhao C, Barry TS, Isacson C, Richardson MS, et al. Ovarian mucinous tumors associated with mature cystic teratomas: morphologic and immunohistochemical analysis identifies a subset of potential teratomatous origin that shares features of lower gastrointestinal tract mucinous tumors more commonly encountered as secondary tumors in the ovary. Am J Surg Pathol. 2007;31(6):854–869. doi: 10.1097/PAS.0b013e31802efb45. PubMed DOI

Alvarado-Cabrero I, Rodríguez-Gómez A, Castelan-Pedraza J, Valencia-Cedillo R. Metastatic ovarian tumors: a clinicopathologic study of 150 cases. Anal Quant Cytopathol Histpathol. 2013;35(5):241–248. PubMed

Acs G, Pasha T, Zhang PJ. WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol. 2004;23(2):110–118. doi: 10.1097/00004347-200404000-00004. PubMed DOI

Neunteufel W, Breitenecker G. Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA. Gynecol Oncol. 1989;32(3):297–302. doi: 10.1016/0090-8258(89)90628-8. PubMed DOI

Viale G, Gambacorta M, Dell'Orto P, Coggi G. Coexpression of cytokeratins and vimentin in common epithelial tumours of the ovary: an immunocytochemical study of eighty-three cases. Virchows Arch A Pathol Anat Histopathol. 1988;413(2):91–101. doi: 10.1007/BF00749670. PubMed DOI

Dabbs DJ, Geisinger KR. Common epithelial ovarian tumors. Immunohistochemical intermediate filament profiles. Cancer. 1988;62(2):368–374. doi: 10.1002/1097-0142(19880715)62:2<368::AID-CNCR2820620223>3.0.CO;2-Z. PubMed DOI

Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13(9):962–972. doi: 10.1038/modpathol.3880175. PubMed DOI

Chu PG, Schwarz RE, Lau SK, Yen Y, Weiss LM. Immunohistochemical staining in the diagnosis of pancreatobiliary and ampulla of Vater adenocarcinoma: application of CDX2, CK17, MUC1, and MUC2. Am J Surg Pathol. 2005;29(3):359–367. doi: 10.1097/01.pas.0000149708.12335.6a. PubMed DOI

Bewick V, Cheek L, Ball J. Statistics review 8: qualitative data - tests of association. Crit Care. 2004;8(1):46–53. doi: 10.1186/cc2428. PubMed DOI PMC

McHugh ML. The chi-square test of independence. Biochem Med (Zagreb) 2013;23(2):143–149. doi: 10.11613/BM.2013.018. PubMed DOI PMC

Lee KR, Young RH. The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases. Am J Surg Pathol. 2003;27(3):281–292. doi: 10.1097/00000478-200303000-00001. PubMed DOI

Khunamornpong S, Suprasert P, Pojchamarnwiputh S, Na Chiangmai W, Settakorn J, Siriaunkgul S. Primary and metastatic mucinous adenocarcinomas of the ovary: evaluation of the diagnostic approach using tumor size and laterality. Gynecol Oncol. 2006;101(1):152–157. doi: 10.1016/j.ygyno.2005.10.008. PubMed DOI

Yemelyanova AV, Vang R, Judson K, Wu LS, Ronnett BM. Distinction of primary and metastatic mucinous tumors involving the ovary: analysis of size and laterality data by primary site with reevaluation of an algorithm for tumor classification. Am J Surg Pathol. 2008;32(1):128–138. doi: 10.1097/PAS.0b013e3180690d2d. PubMed DOI

Okamoto T, Matsumura N, Mandai M, Oura T, Yamanishi Y, Horiuchi A, et al. Distinguishing primary from secondary mucinous ovarian tumors: an algorithm using the novel marker DPEP1. Mod Pathol. 2011;24(2):267–276. doi: 10.1038/modpathol.2010.204. PubMed DOI

Jung ES, Bae JH, Lee A, Choi YJ, Park JS, Lee KY. Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality. J Korean Med Sci. 2010;25(2):220–225. doi: 10.3346/jkms.2010.25.2.220. PubMed DOI PMC

Maeda-Taniguchi M, Ueda Y, Miyake T, Miyatake T, Kimura T, Yoshino K, et al. Metastatic mucinous adenocarcinoma of the ovary is characterized by advanced patient age, small tumor size, and elevated serum CA125. Gynecol Obstet Investig. 2011;72(3):196–202. doi: 10.1159/000323962. PubMed DOI

Hu J, Khalifa RD, Roma AA, Fadare O. The pathologic distinction of primary and metastatic mucinous tumors involving the ovary: a re-evaluation of algorithms based on gross features. Ann Diagn Pathol. 2018;37:1–6. doi: 10.1016/j.anndiagpath.2018.07.001. PubMed DOI

Simons M, Bolhuis T, De Haan AF, Bruggink AH, Bulten J, Massuger LF, et al. A novel algorithm for better distinction of primary mucinous ovarian carcinomas and mucinous carcinomas metastatic to the ovary. Virchows Arch. 2019;474(3):289–296. doi: 10.1007/s00428-018-2504-0. PubMed DOI PMC

Casey L, Singh N. Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances. Histopathology. 2020;76(1):37–51. doi: 10.1111/his.13985. PubMed DOI

Leen SL, Singh N. Pathology of primary and metastatic mucinous ovarian neoplasms. J Clin Pathol. 2012;65(7):591–595. doi: 10.1136/jclinpath-2011-200162. PubMed DOI

Yoshida H, Tanaka H, Tsukada T, Abeto N, Kobayashi-Kato M, Tanase Y, et al. Gross mucinous multinodular appearance aids in the identification of ovarian metastases in low-grade appendiceal mucinous neoplasms during intraoperative consultation. Ann Diagn Pathol. 2021;50:151641. doi: 10.1016/j.anndiagpath.2020.151641. PubMed DOI

Young RH, Hart WR. Metastases from carcinomas of the pancreas simulating primary mucinous tumors of the ovary. A report of seven cases. Am J Surg Pathol. 1989;13(9):748–756. doi: 10.1097/00000478-198909000-00004. PubMed DOI

Young RH, Scully RE. Ovarian metastases from carcinoma of the gallbladder and extrahepatic bile ducts simulating primary tumors of the ovary. A report of six cases. Int J Gynecol Pathol. 1990;9(1):60–72. doi: 10.1097/00004347-199001000-00006. PubMed DOI

Boger-Megiddo I, Weiss NS. Histologic subtypes and laterality of primary epithelial ovarian tumors. Gynecol Oncol. 2005;97(1):80–83. doi: 10.1016/j.ygyno.2004.11.054. PubMed DOI

Kim DD, Park IJ, Kim HC, Yu CS, Kim JC. Ovarian metastases from colorectal cancer: a clinicopathological analysis of 103 patients. Color Dis. 2009;11(1):32–38. doi: 10.1111/j.1463-1318.2008.01543.x. PubMed DOI

Lash RH, Hart WR. Intestinal adenocarcinomas metastatic to the ovaries. A clinicopathologic evaluation of 22 cases. Am J Surg Pathol. 1987;11(2):114–121. doi: 10.1097/00000478-198702000-00005. PubMed DOI

Ursem C, Zhou M, Paciorek A, Atreya CE, Ko AH, Venook A, et al. Clinicopathologic Characteristics and Impact of Oophorectomy for Ovarian Metastases from Colorectal Cancer. Oncologist. 2020. PubMed PMC

Ma F, Li Y, Li W, Kang W, Liu H, Ma S, et al. Metastasectomy improves the survival of gastric Cancer patients with Krukenberg tumors: a retrospective analysis of 182 patients. Cancer Manag Res. 2019;11:10573–10580. doi: 10.2147/CMAR.S227684. PubMed DOI PMC

Lobo J, Machado B, Vieira R, Bartosch C. The challenge of diagnosing a malignancy metastatic to the ovary: clinicopathological characteristics vary and morphology can be different from that of the corresponding primary tumor. Virchows Arch. 2017;470(1):69–80. doi: 10.1007/s00428-016-2029-3. PubMed DOI

Jeung YJ, Ok HJ, Kim WG, Kim SH, Lee TH. Krukenberg tumors of gastric origin versus colorectal origin. Obstet Gynecol Sci. 2015;58(1):32–39. doi: 10.5468/ogs.2015.58.1.32. PubMed DOI PMC

Feng Q, Pei W, Zheng ZX, Bi JJ, Yuan XH. Clinicopathologic characteristics and prognostic factors of 63 gastric cancer patients with metachronous ovarian metastasis. Cancer Biol Med. 2013;10(2):86–91. PubMed PMC

Lu LC, Shao YY, Hsu CH, Hsu C, Cheng WF, Lin YL, et al. Metastasectomy of Krukenberg tumors may be associated with survival benefits in patients with metastatic gastric cancer. Anticancer Res. 2012;32(8):3397–3401. PubMed

Qiu L, Yang T, Shan XH, Hu MB, Li Y. Metastatic factors for Krukenberg tumor: a clinical study on 102 cases. Med Oncol. 2011;28(4):1514–1519. doi: 10.1007/s12032-010-9610-4. PubMed DOI

Tan KL, Tan WS, Lim JF, Eu KW. Krukenberg tumors of colorectal origin: a dismal outcome--experience of a tertiary center. Int J Color Dis. 2010;25(2):233–238. doi: 10.1007/s00384-009-0796-x. PubMed DOI

Mondal SK, Banyopadhyay R, Nag DR, Roychowdhury S, Mondal PK, Sinha SK. Histologic pattern, bilaterality and clinical evaluation of 957 ovarian neoplasms: a 10-year study in a tertiary hospital of eastern India. J Cancer Res Ther. 2011;7(4):433–437. doi: 10.4103/0973-1482.92011. PubMed DOI

Khunamornpong S, Suprasert P, Chiangmai WN, Siriaunkgul S. Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand. Int J Gynecol Cancer. 2006;16(Suppl 1):132–138. doi: 10.1136/ijgc-00009577-200602001-00022. PubMed DOI

Young RH. From krukenberg to today: the ever present problems posed by metastatic tumors in the ovary: part I. historical perspective, general principles, mucinous tumors including the krukenberg tumor. Adv Anat Pathol. 2006;13(5):205–227. doi: 10.1097/01.pap.0000213038.85704.e4. PubMed DOI

Young RH. From Krukenberg to today: the ever present problems posed by metastatic tumors in the ovary. Part II Adv Anat Pathol. 2007;14(3):149–177. doi: 10.1097/PAP.0b013e3180504abf. PubMed DOI

Holtz F, Hart WR. Krukenberg tumors of the ovary: a clinicopathologic analysis of 27 cases. Cancer. 1982;50(11):2438–2447. doi: 10.1002/1097-0142(19821201)50:11<2438::AID-CNCR2820501132>3.0.CO;2-X. PubMed DOI

El-Safadi S, Stahl U, Tinneberg HR, Hackethal A, Muenstedt K. Primary signet ring cell mucinous ovarian carcinoma: a case report and literature review. Case Rep Oncol. 2010;3(3):451–457. doi: 10.1159/000323003. PubMed DOI PMC

Kim JH, Cha HJ, Kim KR, Kim K. Primary ovarian signet ring cell carcinoma: a rare case report. Mol Clin Oncol. 2018;9(2):211–214. PubMed PMC

Yu B, Raj MS. Pseudomyxoma Peritonei. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC; 2020.

Simons M, Simmer F, Bulten J, Ligtenberg MJ, Hollema H, van Vliet S, et al. Two types of primary mucinous ovarian tumors can be distinguished based on their origin. Mod Pathol. 2020;33(4):722–733. doi: 10.1038/s41379-019-0401-y. PubMed DOI

Yan F, Shi F, Li X, Yu C, Lin Y, Li Y, et al. Clinicopathological characteristics of Pseudomyxoma Peritonei originated from ovaries. Cancer Manag Res. 2020;12:7569–7578. doi: 10.2147/CMAR.S264474. PubMed DOI PMC

Guerrieri C, Frånlund B, Fristedt S, Gillooley JF, Boeryd B. Mucinous tumors of the vermiform appendix and ovary, and pseudomyxoma peritonei: histogenetic implications of cytokeratin 7 expression. Hum Pathol. 1997;28(9):1039–1045. doi: 10.1016/S0046-8177(97)90057-5. PubMed DOI

Ates Ozdemir D, Usubutun A. PAX2, PAX8 and CDX2 expression in metastatic mucinous, primary ovarian mucinous and Seromucinous tumors and review of the literature. Pathol Oncol Res. 2016;22(3):593–599. doi: 10.1007/s12253-016-0040-2. PubMed DOI

Werling RW, Yaziji H, Bacchi CE, Gown AM. CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol. 2003;27(3):303–310. doi: 10.1097/00000478-200303000-00003. PubMed DOI

Berg KB, Schaeffer DF. SATB2 as an Immunohistochemical marker for colorectal adenocarcinoma: a concise review of benefits and pitfalls. Arch Pathol Lab Med. 2017;141(10):1428–1433. doi: 10.5858/arpa.2016-0243-RS. PubMed DOI

Vang R, Gown AM, Barry TS, Wheeler DT, Yemelyanova A, Seidman JD, et al. Cytokeratins 7 and 20 in primary and secondary mucinous tumors of the ovary: analysis of coordinate immunohistochemical expression profiles and staining distribution in 179 cases. Am J Surg Pathol. 2006;30(9):1130–1139. doi: 10.1097/01.pas.0000213281.43036.bb. PubMed DOI

Ackroyd SA, Goetsch L, Brown J, Houck K, Wang C, Hernandez E. Pancreaticobiliary metastasis presenting as primary mucinous ovarian neoplasm: a systematic literature review. Gynecol Oncol Rep. 2019;28:109–115. doi: 10.1016/j.gore.2019.03.012. PubMed DOI PMC

Chuang SC, Lee KT, Tsai KB, Sheen PC, Nagai E, Mizumoto K, et al. Immunohistochemical study of DPC4 and p53 proteins in gallbladder and bile duct cancers. World J Surg. 2004;28(10):995–1000. doi: 10.1007/s00268-004-7447-8. PubMed DOI

Goldstein NS, Bassi D, Uzieblo A. WT1 is an integral component of an antibody panel to distinguish pancreaticobiliary and some ovarian epithelial neoplasms. Am J Clin Pathol. 2001;116(2):246–252. doi: 10.1309/8X4T-35B7-7529-QE7X. PubMed DOI

Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–52316. doi: 10.18632/oncotarget.10740. PubMed DOI PMC

Lerwill MF, Young RH. Ovarian metastases of intestinal-type gastric carcinoma: a clinicopathologic study of 4 cases with contrasting features to those of the Krukenberg tumor. Am J Surg Pathol. 2006;30(11):1382–1388. doi: 10.1097/01.pas.0000213256.75316.4a. PubMed DOI

Omranipour R, Abasahl A. Ovarian metastases in colorectal cancer. Int J Gynecol Cancer. 2009;19(9):1524–1528. doi: 10.1111/IGC.0b013e3181a84011. PubMed DOI

Erroi F, Scarpa M, Angriman I, Cecchetto A, Pasetto L, Mollica E, et al. Ovarian metastasis from colorectal cancer: prognostic value of radical oophorectomy. J Surg Oncol. 2007;96(2):113–117. doi: 10.1002/jso.20803. PubMed DOI

Muthukrishnan S, Naganathbabu OL, Murugesan SD, Srinivasan UP, Amudhan A, Rajendran S. Krukenberg tumours from gastrointestinal cancers-analysis from a tertiary care Centre in India. J Gastrointest Oncol. 2018;9(6):1164–1167. doi: 10.21037/jgo.2018.07.03. PubMed DOI PMC

Lee KC, Lin H, ChangChien CC, Fu HC, Tsai CC, Wu CH, et al. Difficulty in diagnosis and different prognoses between colorectal cancer with ovarian metastasis and advanced ovarian cancer: an empirical study of different surgical adoptions. Taiwan J Obstet Gynecol. 2017;56(1):62–67. doi: 10.1016/j.tjog.2015.02.009. PubMed DOI

Riihimäki M, Hemminki A, Sundquist J, Hemminki K. Patterns of metastasis in colon and rectal cancer. Sci Rep. 2016;6:29765. doi: 10.1038/srep29765. PubMed DOI PMC

Kondi-Pafiti A, Kairi-Vasilatou E, Iavazzo C, Dastamani C, Bakalianou K, Liapis A, et al. Metastatic neoplasms of the ovaries: a clinicopathological study of 97 cases. Arch Gynecol Obstet. 2011;284(5):1283–1288. doi: 10.1007/s00404-011-1847-4. PubMed DOI

Lee SJ, Bae JH, Lee AW, Tong SY, Park YG, Park JS. Clinical characteristics of metastatic tumors to the ovaries. J Korean Med Sci. 2009;24(1):114–119. doi: 10.3346/jkms.2009.24.1.114. PubMed DOI PMC

Bruls J, Simons M, Overbeek LI, Bulten J, Massuger LF, Nagtegaal ID. A national population-based study provides insight in the origin of malignancies metastatic to the ovary. Virchows Arch. 2015;467(1):79–86. doi: 10.1007/s00428-015-1771-2. PubMed DOI PMC

Li W, Wang H, Wang J. L VF, Zhu X, Wang Z. ovarian metastases resection from extragenital primary sites: outcome and prognostic factor analysis of 147 patients. BMC Cancer. 2012;12:278. doi: 10.1186/1471-2407-12-278. PubMed DOI PMC

Skírnisdóttir I, Garmo H, Holmberg L. Non-genital tract metastases to the ovaries presented as ovarian tumors in Sweden 1990-2003: occurrence, origin and survival compared to ovarian cancer. Gynecol Oncol. 2007;105(1):166–171. doi: 10.1016/j.ygyno.2006.11.005. PubMed DOI

Moore RG, Chung M, Granai CO, Gajewski W, Steinhoff MM. Incidence of metastasis to the ovaries from nongenital tract primary tumors. Gynecol Oncol. 2004;93(1):87–91. doi: 10.1016/j.ygyno.2003.12.039. PubMed DOI

Demopoulos RI, Touger L, Dubin N. Secondary ovarian carcinoma: a clinical and pathological evaluation. Int J Gynecol Pathol. 1987;6(2):166–175. doi: 10.1097/00004347-198706000-00008. PubMed DOI

Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract. Analysis of 325 cases. Cancer. 1984;53(9):1978–1984. doi: 10.1002/1097-0142(19840501)53:9<1978::AID-CNCR2820530929>3.0.CO;2-1. PubMed DOI

Fujiwara K, Ohishi Y, Koike H, Sawada S, Moriya T, Kohno I. Clinical implications of metastases to the ovary. Gynecol Oncol. 1995;59(1):124–128. doi: 10.1006/gyno.1995.1278. PubMed DOI

Board WCoTE . Female genital Tumours: IARC press. 2020. p. 631.

Garcia A, De la Torre J, Castellvi J, Gil A, Lopez M. Ovarian metastases caused by cholangiocarcinoma: a rare Krukenberg's tumour simulating a primary neoplasm of the ovary: a two-case study. Arch Gynecol Obstet. 2004;270(4):281–284. doi: 10.1007/s00404-003-0508-7. PubMed DOI

Gorringe KL, Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, et al. Therapeutic options for mucinous ovarian carcinoma. Gynecol Oncol. 2020;156(3):552–560. doi: 10.1016/j.ygyno.2019.12.015. PubMed DOI PMC

Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. 2019;10(1):3935. doi: 10.1038/s41467-019-11862-x. PubMed DOI PMC

Anglesio MS, Kommoss S, Tolcher MC, Clarke B, Galletta L, Porter H, et al. Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas. J Pathol. 2013;229(1):111–120. doi: 10.1002/path.4088. PubMed DOI

Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, et al. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms. BMC Cancer. 2015;15:415. doi: 10.1186/s12885-015-1421-8. PubMed DOI PMC

Rechsteiner M, Zimmermann AK, Wild PJ, Caduff R, von Teichman A, Fink D, et al. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Exp Mol Pathol. 2013;95(2):235–241. doi: 10.1016/j.yexmp.2013.08.004. PubMed DOI

Ross JS, Ali SM, Wang K, Palmer G, Yelensky R, Lipson D, et al. Comprehensive genomic profiling of epithelial ovarian cancer by next generation sequencing-based diagnostic assay reveals new routes to targeted therapies. Gynecol Oncol. 2013;130(3):554–559. doi: 10.1016/j.ygyno.2013.06.019. PubMed DOI

Teer JK, Yoder S, Gjyshi A, Nicosia SV, Zhang C, Monteiro ANA. Mutational heterogeneity in non-serous ovarian cancers. Sci Rep. 2017;7(1):9728. doi: 10.1038/s41598-017-10432-9. PubMed DOI PMC

Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD. Australian ovarian Cancer study G, et al. pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res. 2012;18(19):5267–5277. doi: 10.1158/1078-0432.CCR-12-1103. PubMed DOI

Vereczkey I, Serester O, Dobos J, Gallai M, Szakacs O, Szentirmay Z, et al. Molecular characterization of 103 ovarian serous and mucinous tumors. Pathol Oncol Res. 2011;17(3):551–559. doi: 10.1007/s12253-010-9345-8. PubMed DOI

Ryland GL, Hunter SM, Doyle MA, Caramia F, Li J, Rowley SM, et al. Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors. Genome Med. 2015;7(1):87. doi: 10.1186/s13073-015-0210-y. PubMed DOI PMC

Ohnishi K, Nakayama K, Ishikawa M, Ishibashi T, Yamashita H, Nakamura K, et al. Mucinous borderline ovarian tumors with BRAF(V600E) mutation may have low risk for progression to invasive carcinomas. Arch Gynecol Obstet. 2020;302(2):487–495. doi: 10.1007/s00404-020-05638-8. PubMed DOI PMC

Sadlecki P, Walentowicz P, Bodnar M, Marszalek A, Grabiec M, Walentowicz-Sadlecka M. Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers. Tumour Biol. 2017;39(5):1010428317706230. doi: 10.1177/1010428317706230. PubMed DOI

Brockbank EC, Evans J, Singh N, Shepherd JH, Jeyarajah AR. Ovarian recurrence from a stage 1b1 cervical adenocarcinoma previously treated with radical vaginal trachelectomy: a case report. Gynecol Oncol Case Rep. 2012;2(2):51–53. doi: 10.1016/j.gynor.2012.01.001. PubMed DOI PMC

Vang R, Gown AM, Farinola M, Barry TS, Wheeler DT, Yemelyanova A, et al. p16 expression in primary ovarian mucinous and endometrioid tumors and metastatic adenocarcinomas in the ovary: utility for identification of metastatic HPV-related endocervical adenocarcinomas. Am J Surg Pathol. 2007;31(5):653–663. doi: 10.1097/01.pas.0000213369.71676.25. PubMed DOI

Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005;29(3):281–294. doi: 10.1097/01.pas.0000152136.81771.12. PubMed DOI

Ronnett BM, Yemelyanova AV, Vang R, Gilks CB, Miller D, Gravitt PE, et al. Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol. 2008;32(12):1835–1853. doi: 10.1097/PAS.0b013e3181758831. PubMed DOI

Rambau PF, Vierkant RA, Intermaggio MP, Kelemen LE, Goodman MT, Herpel E, et al. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an ovarian tumor tissue analysis consortium study. J Pathol Clin Res. 2018;4(4):250–261. doi: 10.1002/cjp2.109. PubMed DOI PMC

Carleton C, Hoang L, Sah S, Kiyokawa T, Karamurzin YS, Talia KL, et al. A detailed Immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas. Am J Surg Pathol. 2016;40(5):636–644. doi: 10.1097/PAS.0000000000000578. PubMed DOI PMC

The cytokeratin 17 expression in primary ovarian tumors has diagnostic but not prognostic significance